• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

IRLAB Therapeutics

1.24 SEK

-2.05 %

Less than 1K followers

IRLAB A

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.05 %
+0.57 %
-20.37 %
-35.57 %
-35.57 %
-81.04 %
-84.55 %
-96.73 %
-88.41 %

IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.

Read more
Market cap
175.82M SEK
Turnover
80.58K SEK
Revenue
57.46M
EBIT %
-162.55 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17/6
2026

General meeting '26

26/8
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

Regulatory press releaseyesterday

Teckningsperioden i IRLAB:s företrädesemission inleds idag

IRLAB Therapeutics
Regulatory press releaseyesterday

The subscription period in IRLAB’s rights issue commences today

IRLAB Therapeutics
Regulatory press release6/5/2026, 2:00 PM

IRLAB offentliggör informationsdokument i samband med företrädesemissionen och meddelar att ytterligare teckningsåtaganden erhållits

IRLAB Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/5/2026, 2:00 PM

IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received

IRLAB Therapeutics
Regulatory press release6/5/2026, 11:50 AM

Kommuniké från extra bolagsstämma i IRLAB Therapeutics AB

IRLAB Therapeutics
Regulatory press release6/5/2026, 11:50 AM

Report from the Extraordinary General Meeting of IRLAB Therapeutics AB

IRLAB Therapeutics
Press release6/3/2026, 5:00 AM

IRLAB medverkar vid Aktiedagarna i Stockholm den 9 juni

IRLAB Therapeutics
Press release6/3/2026, 5:00 AM

IRLAB participates at Aktiedagarna in Stockholm on June 9.

IRLAB Therapeutics
Regulatory press release5/29/2026, 5:30 PM

KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB

IRLAB Therapeutics
Regulatory press release5/6/2026, 5:00 AM

IRLAB publicerar delårsrapport för perioden januari – mars 2026

IRLAB Therapeutics
Regulatory press release5/6/2026, 5:00 AM

IRLAB publishes interim report for the period January - March 2026

IRLAB Therapeutics
Regulatory press release5/5/2026, 7:03 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB

IRLAB Therapeutics
Regulatory press release5/5/2026, 7:03 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB

IRLAB Therapeutics
Regulatory press release5/5/2026, 6:41 AM

IRLAB beslutar om företrädesemission om cirka 68 MSEK med övertilldelningsemission samt erhåller förlängd lånefinansiering

IRLAB Therapeutics
Regulatory press release5/5/2026, 6:41 AM

IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing

IRLAB Therapeutics
Press release4/30/2026, 5:00 AM

IRLAB: Inbjudan till presentation och webcast av delårsrapport för det första kvartalet för 2026

IRLAB Therapeutics
Press release4/30/2026, 5:00 AM

IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast

IRLAB Therapeutics
Regulatory press release4/29/2026, 2:30 PM

IRLAB publicerar årsredovisning för 2025

IRLAB Therapeutics
Regulatory press release4/29/2026, 2:30 PM

IRLAB publishes the Annual Report for 2025

IRLAB Therapeutics
Regulatory press release4/17/2026, 7:50 AM

Valberedningens förslag till styrelse inför IRLAB Therapeutics årsstämman 2026

IRLAB Therapeutics